全部分类
  • AZ-23 (AZ23)
AZ-23 (AZ23)的可视化放大

AZ-23 (AZ23)

AZ-23 (AZ23) 是一种 ATP 竞争性和口服生物可利用的 Trk 激酶 A/B/C 抑制剂,IC50 为 2 nM (TrkA)、8 nM (TrkB)、24 nM (FGFR1)、52 nM (Flt3)、55分别为 nM (Ret)、84 nM (MuSk)、99 nM (Lck)。

此产品仅用于科学研究,我们不为任何个人用途提供产品和服务

AZ-23 (AZ23)的二维码
  • 库存: 现货
可选规格
  • 包装
    价格
    促销价
    数量
  • 2mg
    ¥1200.00
    960.00
    - +
  • 5mg
    ¥2375.00
    1900.00
    - +
  • 10mg
    ¥3850.00
    3080.00
    - +
  • 25mg
    ¥8125.00
    6500.00
    - +
  • 50mg
    ¥12287.00
    9830.00
    - +
  • 100mg
    ¥20662.00
    16530.00
    - +
已选 0 0
金额: ¥0.00
首页 收藏
  • 货号: ajce50422
  • CAS: 915720-21-7
  • 别名: 5-氯-N-[(1S)-1-(5-氟吡啶-2-基)乙基]-N'-(5-异丙氧基-1H-吡唑-3-基)嘧啶-2,4-二胺,AZ23; AZ 23
  • 分子式: C17H19ClFN7O
  • 分子量: 391.83
  • 纯度: >98%
  • 溶解度: DMSO : 125 mg/mL (319.02 mM)
  • 储存: Store at -20°C
  • 库存: 现货

Background

AZ-23 is an ATP-competitive and orally bioavailable Trk kinase A/B/C inhibitor with IC50s of 2 nM (TrkA), 8 nM (TrkB), 24 nM (FGFR1), 52 nM (Flt3), 55 nM (Ret), 84 nM (MuSk), 99 nM (Lck), respectively.


AZ-23 potently and selectivity inhibits Trk phosphorylation in cells. AZ-23 potently inhibits Trk-mediated survival (EC50 of 2 nM). AZ-23 Inhibits Trk-Dependent Survival in MCF10ATrkA-δ and TF-1 Cell Lines[1].


AZ-23 shows in vivo TrkA kinase inhibition and efficacy in mice following oral administration in a TrkA-driven allograft model and significant tumor growth inhibition in a Trk-expressing xenograft model of neuroblastoma[1].


[1]. Thress K, et al. Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway. Mol Cancer Ther. 2009 Jul; 8(7):1818-27.

Protocol

Cell experiment:

Exponentially growing TF-1 cells are treated with various concentrations of AZ-23 and then incubated for an additional 72 h at 37°C in either growth or basal medium plus 100 ng/mL NGF. Cell proliferation is measured using MTS solution[1].

Animal experiment:

Mice[1] Tumor-bearing mice are given a single, oral dose of compound and individual mice are sacrificed at various time points postdose (2, 6, 16, or 24 hours). Tumors are excised and homogenized and the resulting tumor lysates are analyzed using an ELISA for pTrkA[1].

参考文献:

[1]. Thress K, et al. Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway. Mol Cancer Ther. 2009 Jul; 8(7):1818-27.

没有评价数据

温馨提示 ×
商品已成功加入购物车!
购物车共 0 件商品
去购物车结算